Bouloux, P and Warne, DW and Loumaye, E (2002) Efficacy and safety of recombinant human follicle-stimulating hormone in men with isolated hypogonadotropic hypogonadism. Fertility and Sterility , 77 (2) 270 - 273.
Full text not available from this repository.
Abstract
OBJECTIVE: To assess the efficacy and safety of recombinant human follicle-stimulating hormone (rhFSH; follitropin alpha) in increasing sperm concentration in 26 men with severe isolated hypogonadotropic hypogonadism (IHH). DESIGN: Clinical and endocrine studies using an open design. SETTING: Six university clinical sites in three European countries. PATIENT(S): Azoospermatic patients aged 16 to 48 years with IHH. INTERVENTION(S): Patients received hCG for up to 6 months before 18 months of treatment with rhFSH. Sperm count, motility, and morphology were assessed every 3 months. MAIN OUTCOME MEASURE(S): Achievement of a sperm concentration of 1.5 x 10(6)/mL. RESULT(S): Spermatogenesis was achieved in 15 of 19 patients who could be evaluated, 12 achieving a sperm concentration of > or =1.5 x 10(6)/mL. CONCLUSION(S): With hCG, rhFSH is effective in initiating spermatogenesis in patients with IHH, and is well tolerated
| Type: | Article |
|---|---|
| Title: | Efficacy and safety of recombinant human follicle-stimulating hormone in men with isolated hypogonadotropic hypogonadism |
| Additional information: | UI - 21679148 DA - 20020131 IS - 0015-0282 LA - eng PT - Clinical Trial PT - Journal Article PT - Multicenter Study RN - 0 (Chorionic Gonadotropin) RN - 0 (Recombinant Proteins) RN - 50-28-2 (Estradiol) RN - 57-85-2 (Testosterone) RN - 57285-09-3 (Inhibins) RN - 9002-68-0 (Follicle Stimulating Hormone) SB - IM |
| Keywords: | Achievement, Aged, ALPHA, American, clinical, Concentration, design, EFFICACY, endocrine, English, european, Follicle Stimulating Hormone, FOLLICLE-STIMULATING-HORMONE, Follitropin, Germany, GONADOTROPIN THERAPY, HCG, hormone, hypogonadism, HYPOGONADOTROPIC HYPOGONADISM, Male, medicine, MEN, morphology, motility, NEW-YORK, Open, outcome, Patient, patients, recombinant, recombinant human follicle-stimulating hormone, reproductive, Reproductive Medicine, Safety, Science, Setting, SITE, SITES, societies, sperm, Sperm Count, Spermatogenesis, Testis, treatment, USA, administration & dosage, adolescent, adult, adverse effects, Blood, Chorionic Gonadotropin, Clinical trial, CLINICAL-TRIAL, drug effects, drug therapy, ESTRADIOL, Female, follicle, GONADOTROPIN, IM, inhibin, Inhibins, LA, Middle Age, MULTICENTER, Multicenter Studies, Oligospermia, physiology, physiopathology, Pregnancy, PROTEIN, Proteins, Recombinant Proteins, Sperm Motility, Support, Non-U.S.Gov't, Testosterone, therapeutic use, TRIAL |
| UCL classification: | UCL > School of Life and Medical Sciences > Faculty of Medical Sciences > Medicine (Division of) > Metabolism and Experimental Therapeutics |
Archive Staff Only: edit this record